

SUPPLEMENTAL MATERIALS

Supplementary Table 1: Sequences of primers

ACC1 – S: GAG-CAA-GGG-ATA-AGT-TTG-AG
ACC1 – AS: AGG-TGC-ATC-TTG-TGA-TTA-GC

ATP5B-S: TGT-GTT-TGC-TGG-TGT-TGG-TG
ATP5B-AS: ATC-TTG-ACC-TTC-TTG-GTC-TCT-G

FAS – S: CAC-AGG-CAG-AAG-CTG-TAC-AC
FAS – AS: ATG-TTC-TCC-ACG-GCA-GTG-TC

FTO – S: GAG-TTT-GAG-TGG-CTG-AGG-CA
FTO – AS: GGG-AGC-CCC-TCT-CTT-TTA-AC

GPAT – S: CTA-CGA-AGG-AGG-TTG-ATT-GC
GPAT – AS: CTG-TGT-CTG-TAG-AGG-AGC-AG

HPRT – S: TTG-CTG-ACC-TGC-TGG-ATT-AC
HPRT – AS: AGT-TGA-GAG-ATC-ATC-TCC-AC

PGC1 α – S: TCC-TCT-GAC-CCC-AGA-GTC-AC
PGC1 α – AS: CTT-GGT-TGG-CTT-TAT-GAG-GAG-G

PPAR γ - S: TCT-CTC-CGT-AAT-GGA-AGA-CC
PPAR γ - AS: GCA-TTA-TGA-GAC-ATC-CCC-AC

SOD2-S: TGC-TGC-TTG-TCC-AAA-TCA-GG
SOD2-AS: ACT-GAA-GGT-AGT-AAG-CGT-GC

TBP-S: TGG-TGT-GCA-CAG-GAG-CCA-AG
TBP-AS: TTC-ACA-TCA-CAG-CTC-CCC-AC

UQCR-S: CCA-AGC-CTC-AGG-ATG-GAC-AAG
UQCR-AS: TCA-CCT-GTG-CCA-CTC-CAG-CTA-C

Supplementary Table 2: Clinical and metabolic characteristics of the subjects before and after Rosiglitazone treatment.

	Type 2 diabetic subjects	
	Before treatment	After treatment
n	6	
Men/Women	3/3	
Age (years)	52.6 ± 2.9	
BMI (kg/m ²)	29.5 ± 6.9	30.1 ± 0.7
Glucose (mmol/L)	6.9 ± 0.4	6.3 ± 0.6
Insulin (pmol/L)	12.3 ± 2.0	9.8 ± 1.1
Triglycerides (mmol/L)	1.3 ± 0.2	1.3 ± 0.4
Non esterified fatty acid (μmol/L)	522.1 ± 59.9	422.0 ± 62.8
Glucose disposal rate (mg/(kg.min))	5.58 ± 0.85	7.81 ± 0.84*
Glucose oxidation rate (mg/(kg.min))	0.49 ± 0.23	1.35 ± 0.30 *
Lipid oxidation rate (mg/(kg.min))	0.64 ± 0.20	0.53 ± 0.09

* p < 0.05 when comparing type 2 diabetic subjects after rosiglitazone treatment with the same subjects before treatment